Literature DB >> 20375243

Comparison of three anthrax toxin neutralization assays.

Miriam M Ngundi1, Bruce D Meade, Tsai-Lien Lin, Wei-Jen Tang, Drusilla L Burns.   

Abstract

Different types of anthrax toxin neutralization assays have been utilized to measure the antibody levels elicited by anthrax vaccines in both nonclinical and clinical studies. In the present study, we sought to determine whether three commonly used toxin neutralization assays-J774A.1 cell-, RAW 264.7 cell-, and CHO cell-based assays-yield comparable estimates of neutralization activities for sera obtained after vaccination with anthrax vaccines composed of recombinant protective antigen (rPA). In order to compare the assays, sera were assayed alongside a common reference serum sample and the neutralization titers were expressed relative to the titer for the reference sample in each assay. Analysis of sera from rabbits immunized with multiple doses of the rPA vaccine showed that for later bleeds, the quantitative agreement between the assays was good; however, for early bleeds, some heterogeneity in relative neutralization estimates was observed. Analysis of serum samples from rabbits, nonhuman primates, and humans immunized with the rPA vaccine showed that the relative neutralization estimates obtained in the different assays agreed to various extents, depending on the species of origin of the sera examined. We identified differences in the magnitudes of the Fc receptor-mediated neutralization associated with the J774A.1 cell- and RAW 264.7 cell-based assays, which may account for some of the species dependence of the assays. The differences in the relative neutralization estimates among the assays were relatively small and were always less than 2.5-fold. However, because toxin neutralization assays will likely be used to establish the efficacies of new anthrax vaccines, our findings should be considered when assay outputs are interpreted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375243      PMCID: PMC2884435          DOI: 10.1128/CVI.00513-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.

Authors:  P F Fellows; M K Linscott; B E Ivins; M L Pitt; C A Rossi; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

2.  The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

Authors:  S Welkos; S Little; A Friedlander; D Fritz; P Fellows
Journal:  Microbiology       Date:  2001-06       Impact factor: 2.777

3.  Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.

Authors:  Laura Vitale; Diann Blanset; Israel Lowy; Thomas O'Neill; Joel Goldstein; Stephen F Little; Gerard P Andrews; Gary Dorough; Ronald K Taylor; Tibor Keler
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

Review 5.  Anthrax toxins: A paradigm of bacterial immune suppression.

Authors:  Cosima T Baldari; Fiorella Tonello; Silvia Rossi Paccani; Cesare Montecucco
Journal:  Trends Immunol       Date:  2006-07-24       Impact factor: 16.687

6.  Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays.

Authors:  Anita Verma; Miriam M Ngundi; Bruce D Meade; Roberto De Pascalis; Karen L Elkins; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2009-08-05

7.  Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.

Authors:  Kristian S Omland; April Brys; David Lansky; Kristin Clement; Freyja Lynn
Journal:  Clin Vaccine Immunol       Date:  2008-04-16

Review 8.  New insights into the pathogenesis and treatment of anthrax toxin-induced shock.

Authors:  Yan Li; Kevin Sherer; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Biol Ther       Date:  2007-06       Impact factor: 4.388

9.  Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.

Authors:  Han Li; Stephen D Soroka; Thomas H Taylor; Karen L Stamey; Kelly Wallace Stinson; Alison E Freeman; Darbi R Abramson; Rita Desai; Li X Cronin; J Wade Oxford; Joseph Caba; Cynthia Pleatman; Sonal Pathak; Daniel S Schmidt; Vera A Semenova; Sandra K Martin; Patricia P Wilkins; Conrad P Quinn
Journal:  J Immunol Methods       Date:  2008-02-08       Impact factor: 2.303

10.  Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.

Authors:  Zhaochun Chen; Mahtab Moayeri; Devorah Crown; Suzanne Emerson; Inna Gorshkova; Peter Schuck; Stephen H Leppla; Robert H Purcell
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

View more
  13 in total

1.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

2.  Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Authors:  Stylianos Bournazos; Siu-Kei Chow; Nareen Abboud; Arturo Casadevall; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

3.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

4.  Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Authors:  Leslie Wagner; Anita Verma; Bruce D Meade; Karine Reiter; David L Narum; Rebecca A Brady; Stephen F Little; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

5.  Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2.

Authors:  Anita Verma; Mahtab Moayeri; Christopher P Mocca; Danielle O'Mard; Qian Ma; Stephen H Leppla; Drusilla L Burns
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

6.  Targeted silencing of anthrax toxin receptors protects against anthrax toxins.

Authors:  Maria T Arévalo; Ashley Navarro; Chenoa D Arico; Junwei Li; Omar Alkhatib; Shan Chen; Diana Diaz-Arévalo; Mingtao Zeng
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

7.  Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen.

Authors:  Anita Verma; Beth McNichol; Rocío I Domínguez-Castillo; Juan C Amador-Molina; Juan L Arciniega; Karine Reiter; Bruce D Meade; Miriam M Ngundi; Scott Stibitz; Drusilla L Burns
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

8.  Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Authors:  Hang Lu; Jason Catania; Katalin Baranji; Jie Feng; Mili Gu; Janet Lathey; Diane Sweeny; Hannah Sanford; Kavita Sapru; Terry Patamawenu; June-Home Chen; Alan Ng; Zenbework Fesseha; Stefanie Kluepfel-Stahl; Jacob Minang; David Alleva
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

9.  Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.

Authors:  Sean M Kelly; Kristina R Larsen; Ross Darling; Andrew C Petersen; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Vaccine       Date:  2021-06-02       Impact factor: 4.169

10.  SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.

Authors:  Nicola Bak; Shalini Rajagopal; Paul Stickings; Dorothea Sesardic
Journal:  Toxins (Basel)       Date:  2017-07-20       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.